Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma

NCT01973062 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Funding Unavailable

Conditions

Primary Central Nervous System Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: rituximab
RADIATION: yttrium Y 90 ibritumomab tiuxetan

Sponsor

Case Comprehensive Cancer Center